Loading...
A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006)
Agarwala, Sanjiv S. Nagl, Ulrich Guo, Xinghua Bellon, Anne Heyn, Jens Dimova-Dobreva, Miryana Shen, Yu-Ming Schaffar, Gregor Humphrey, Martin Mathieson, Nicola
Agarwala, Sanjiv S.
Nagl, Ulrich
Guo, Xinghua
Bellon, Anne
Heyn, Jens
Dimova-Dobreva, Miryana
Shen, Yu-Ming
Schaffar, Gregor
Humphrey, Martin
Mathieson, Nicola
Citations
Altmetric:
Genre
Journal article
Date
2022-04-17
Advisor
Committee member
Group
Department
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1080/03007995.2022.2061707
Abstract
Objective: The totality-of-evidence approach requires that similarity between a proposed biosimilar and a reference biologic is demonstrated across a range of analytical, preclinical, and clinical parameters to establish biosimilarity. We describe the totality of evidence for Sandoz biosimilar pegfilgrastim (LA-EP2006 [marketed as Ziextenzo]) that supported its regulatory approval in Europe and the United States. Methods: Analytical similarity to the reference biologic [marketed by Amgen as Neulasta] was first investigated with regard to physiochemical quality attributes such as primary structure, pegylation, higher-order structures, variants and impurities, molecular size variants, and formulation (protein content, pH, excipients, etc.). In vitro biological activity studies were performed to examine the primary mechanism of action of pegfilgrastim. Bioequivalence (clinical pharmacokinetics [PK] and pharmacodynamics [PD]) of Sandoz biosimilar pegfilgrastim to the reference biologic was studied in healthy volunteers; efficacy, safety, and immunogenicity were assessed during confirmatory clinical efficacy studies in patients undergoing treatment for breast cancer. Results: No meaningful or relevant differences were identified between Sandoz biosimilar pegfilgrastim and the reference biologic during analytical testing. Similar receptor binding and induction of cellular proliferation in vitro confirmed no functional differences between the biologics. Clinical studies in healthy adult participants demonstrated PK/PD biosimilarity and a similar safety profile between biosimilar and reference pegfilgrastim. Clinical studies in a sensitive patient population also demonstrated similar efficacy, safety, and immunogenicity between Sandoz biosimilar pegfilgrastim and the reference biologic. Conclusions: The totality of evidence confirms that Sandoz biosimilar pegfilgrastim matches the reference biologic and will therefore provide equivalent efficacy and safety in all eligible indications.
Description
Citation
Agarwala, S. S., Nagl, U., Guo, X., Bellon, A., Heyn, J., Dimova-Dobreva, M., … Gattu, S. (2022). A review of the totality of evidence supporting the development and approval of a pegfilgrastim biosimilar (LA-EP2006). Current Medical Research and Opinion, 38(6), 999–1009. https://doi.org/10.1080/03007995.2022.2061707
Citation to related work
Taylor and Francis Group
Has part
Current Medical Research and Opinion, Vol. 38, Iss. 6
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu